Vericel Corporation, a leading player in the regenerative medicine industry, is headquartered in the United States. Founded in 1989, the company has made significant strides in developing innovative cell-based therapies, particularly for patients with severe skin injuries and cartilage damage. Vericel's core products, including Epicel® and MACI®, are distinguished by their ability to harness the body’s own cells to promote healing, setting them apart in the competitive landscape of advanced therapeutics. With a strong presence in the US and expanding operations in key international markets, Vericel has established itself as a pioneer in the field. The company’s commitment to research and development has led to notable achievements, including FDA approvals that underscore its market position. Vericel continues to drive advancements in regenerative medicine, aiming to improve patient outcomes and redefine treatment paradigms.
How does Vericel Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Vericel Corporation's score of 19 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Vericel Corporation, headquartered in the US, currently does not have available carbon emissions data, as indicated by the absence of specific figures for kg CO2e. Additionally, there are no documented reduction targets or climate pledges at this time. The company does not inherit emissions data from any parent organisation, ensuring that all information is directly related to Vericel Corporation itself. As such, the organisation's climate commitments and initiatives remain unspecified, reflecting a need for further transparency and action in addressing carbon emissions and sustainability efforts.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vericel Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
